William Mintz Sells 8,431 Shares of Claritev (NYSE:CTEV) Stock

Claritev (NYSE:CTEV) SVP William Mintz sold 8,431 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $34.24, for a total value of $288,677.44. Following the completion of the transaction, the senior vice president owned 71,195 shares of the company’s stock, valued at $2,437,716.80. This trade represents a 10.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Claritev Price Performance

NYSE CTEV opened at $41.73 on Friday. The stock has a market capitalization of $711.50 million, a price-to-earnings ratio of -2.45 and a beta of 0.74. Claritev has a one year low of $11.50 and a one year high of $74.07. The business’s fifty day moving average is $29.60 and its 200-day moving average is $23.95.

Hedge Funds Weigh In On Claritev

Several large investors have recently modified their holdings of CTEV. Arini Captial Management Ltd bought a new position in Claritev in the 4th quarter worth approximately $64,291,000. Beach Point Capital Management LP grew its stake in Claritev by 77.4% in the 4th quarter. Beach Point Capital Management LP now owns 755,002 shares of the company’s stock valued at $32,276,000 after buying an additional 329,424 shares in the last quarter. AXQ Capital LP bought a new stake in Claritev during the 4th quarter valued at $223,000. Hussman Strategic Advisors Inc. purchased a new stake in shares of Claritev during the fourth quarter worth $449,000. Finally, Public Employees Retirement System of Ohio bought a new position in shares of Claritev in the first quarter worth $38,000. Hedge funds and other institutional investors own 87.15% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Piper Sandler reiterated an “overweight” rating and issued a $73.00 target price on shares of Claritev in a research note on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Claritev in a report on Wednesday, June 24th. Wall Street Zen upgraded Claritev from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Wells Fargo & Company increased their price objective on Claritev from $22.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday. Finally, Barclays assumed coverage on Claritev in a research report on Friday, April 24th. They issued an “overweight” rating and a $28.00 target price for the company. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $42.83.

About Claritev

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.